Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy

Eri Matsuki, Yuiko Tsukada, Aya Nakaya, Kenji Yokoyama, Shinichiro Okamoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.

Original languageEnglish
Pages (from-to)909-914
Number of pages6
JournalInternal Medicine
Volume50
Issue number8
DOIs
Publication statusPublished - 2011

Fingerprint

Langerhans Cell Histiocytosis
Combination Drug Therapy
6-Mercaptopurine
Vinblastine
Prednisone
Therapeutics

Keywords

  • Adults
  • Combination chemotherapy
  • Langerhans cell histiocytosis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy. / Matsuki, Eri; Tsukada, Yuiko; Nakaya, Aya; Yokoyama, Kenji; Okamoto, Shinichiro.

In: Internal Medicine, Vol. 50, No. 8, 2011, p. 909-914.

Research output: Contribution to journalArticle

Matsuki, Eri ; Tsukada, Yuiko ; Nakaya, Aya ; Yokoyama, Kenji ; Okamoto, Shinichiro. / Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy. In: Internal Medicine. 2011 ; Vol. 50, No. 8. pp. 909-914.
@article{ebd7d70d66c0436ca11fe45206260a2a,
title = "Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy",
abstract = "Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.",
keywords = "Adults, Combination chemotherapy, Langerhans cell histiocytosis",
author = "Eri Matsuki and Yuiko Tsukada and Aya Nakaya and Kenji Yokoyama and Shinichiro Okamoto",
year = "2011",
doi = "10.2169/internalmedicine.50.4808",
language = "English",
volume = "50",
pages = "909--914",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "8",

}

TY - JOUR

T1 - Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy

AU - Matsuki, Eri

AU - Tsukada, Yuiko

AU - Nakaya, Aya

AU - Yokoyama, Kenji

AU - Okamoto, Shinichiro

PY - 2011

Y1 - 2011

N2 - Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.

AB - Adult onset Langerhans cell histiocytosis (LCH) is a rare disorder. Its clinical features have been well described in children, however remain poorly defined in adults. Optimal treatment strategy is still under debate. We have encountered two cases of adult onset LCH, which obtained a durable disease control by combination chemotherapy using prednisone, vinblastine and 6-mercaptopurine. Herein, we report their clinical features together with a review of the current literature.

KW - Adults

KW - Combination chemotherapy

KW - Langerhans cell histiocytosis

UR - http://www.scopus.com/inward/record.url?scp=79955551409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955551409&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.50.4808

DO - 10.2169/internalmedicine.50.4808

M3 - Article

C2 - 21498941

AN - SCOPUS:79955551409

VL - 50

SP - 909

EP - 914

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 8

ER -